WO2013072770A3 - Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride - Google Patents
Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride Download PDFInfo
- Publication number
- WO2013072770A3 WO2013072770A3 PCT/IB2012/002860 IB2012002860W WO2013072770A3 WO 2013072770 A3 WO2013072770 A3 WO 2013072770A3 IB 2012002860 W IB2012002860 W IB 2012002860W WO 2013072770 A3 WO2013072770 A3 WO 2013072770A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glimepiride
- atorvastatin
- pharmaceutical formulations
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014124118/15A RU2014124118A (ru) | 2011-11-15 | 2012-11-14 | Фармацевтические препараты, включающие аторвастатин и глимепирид |
EP12826534.5A EP2779999A2 (fr) | 2011-11-15 | 2012-11-14 | Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride |
IN4119CHN2014 IN2014CN04119A (fr) | 2011-11-15 | 2012-11-14 | |
ZA2014/03735A ZA201403735B (en) | 2011-11-15 | 2014-05-22 | Pharmaceutical formulations comprising atorvastatin and glimepiride |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3920/CHE/2011 | 2011-11-15 | ||
IN3920CH2011 | 2011-11-15 | ||
US201261582566P | 2012-01-03 | 2012-01-03 | |
US61/582,566 | 2012-01-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013072770A2 WO2013072770A2 (fr) | 2013-05-23 |
WO2013072770A3 true WO2013072770A3 (fr) | 2013-10-24 |
Family
ID=48430284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/002860 WO2013072770A2 (fr) | 2011-11-15 | 2012-11-14 | Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2779999A2 (fr) |
IN (1) | IN2014CN04119A (fr) |
RU (1) | RU2014124118A (fr) |
WO (1) | WO2013072770A2 (fr) |
ZA (1) | ZA201403735B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230181532A1 (en) * | 2020-05-18 | 2023-06-15 | Board Of Regents, The University Of Texas System | Granules for 3d printing technology |
CN112618499B (zh) * | 2020-12-24 | 2022-09-30 | 石药集团欧意药业有限公司 | 一种格列美脲分散片剂组合物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004110431A1 (fr) * | 2003-06-12 | 2004-12-23 | Warner-Lambert Company Llc | Compositions stables d'atorvastatine preparees par granulation par voie humide |
WO2007072218A2 (fr) * | 2005-06-10 | 2007-06-28 | Combino Pharm, S.L. | Formulations contenant du glimepiride et/ou ses sels |
CN101103990A (zh) * | 2006-07-14 | 2008-01-16 | 北京华安佛医药研究中心有限公司 | 含有磺脲类降糖药物和他汀类降脂药物的组合物 |
WO2009140341A2 (fr) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Compositions d'atorvastatine |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
DE3320582A1 (de) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
EP0680320B1 (fr) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Formulation ci-981, orale, stable et son procede de preparation |
ES2167587T3 (es) | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
SI20109A (sl) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
ES2401598T3 (es) | 2000-04-10 | 2013-04-22 | Teva Pharmaceutical Industries, Ltd. | Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos |
WO2001093859A1 (fr) | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Produit et preparation pharmaceutiques stables |
SI1292293T1 (en) | 2000-06-09 | 2004-06-30 | LEK farmacevtska dru�ba d.d. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
AR030379A1 (es) | 2000-08-22 | 2003-08-20 | Novartis Ag | Combinaciones |
US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
AP2004003112A0 (en) | 2002-02-14 | 2004-09-30 | Ranbaxy Lab Ltd | Formulations of atorvastatin stabilised with alkali metal additions |
US20030171407A1 (en) | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
CA2385529A1 (fr) | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Formulations posologiques stables contenant de l'atorvastatin calcium |
SI21302A (sl) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
US20040147564A1 (en) | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
SI21400A (sl) | 2003-02-12 | 2004-08-31 | LEK farmacevtska družba d.d. | Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
WO2006006021A2 (fr) | 2004-06-28 | 2006-01-19 | Glenmark Pharmaceuticals Limited | Compositions pharmaceutiques stabilisees |
CA2582449A1 (fr) | 2004-09-30 | 2006-04-13 | Dr. Reddy's Laboratories Ltd. | Atorvastatine calcique amorphe |
JP5288791B2 (ja) | 2005-01-28 | 2013-09-11 | 武田薬品工業株式会社 | 難水溶性物質含有微細化組成物 |
US20100029743A1 (en) | 2006-09-27 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
-
2012
- 2012-11-14 IN IN4119CHN2014 patent/IN2014CN04119A/en unknown
- 2012-11-14 WO PCT/IB2012/002860 patent/WO2013072770A2/fr active Application Filing
- 2012-11-14 EP EP12826534.5A patent/EP2779999A2/fr not_active Withdrawn
- 2012-11-14 RU RU2014124118/15A patent/RU2014124118A/ru not_active Application Discontinuation
-
2014
- 2014-05-22 ZA ZA2014/03735A patent/ZA201403735B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004110431A1 (fr) * | 2003-06-12 | 2004-12-23 | Warner-Lambert Company Llc | Compositions stables d'atorvastatine preparees par granulation par voie humide |
WO2007072218A2 (fr) * | 2005-06-10 | 2007-06-28 | Combino Pharm, S.L. | Formulations contenant du glimepiride et/ou ses sels |
CN101103990A (zh) * | 2006-07-14 | 2008-01-16 | 北京华安佛医药研究中心有限公司 | 含有磺脲类降糖药物和他汀类降脂药物的组合物 |
WO2009140341A2 (fr) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Compositions d'atorvastatine |
Non-Patent Citations (2)
Title |
---|
CHOWDHURY S ET AL: "Statistical optimization of fixed dose combination of glimepiride and atorvastatin calcium in immediate release tablet Formulation", INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES : IJPPS, MADHYA PRADESH, IN, vol. 2, no. Suppl. 4, 1 November 2010 (2010-11-01), pages 194 - 200, XP008163345, ISSN: 0975-1491 * |
DATABASE WPI Week 200874, Derwent World Patents Index; AN 2008-M50691, XP002700007 * |
Also Published As
Publication number | Publication date |
---|---|
IN2014CN04119A (fr) | 2015-07-10 |
WO2013072770A2 (fr) | 2013-05-23 |
EP2779999A2 (fr) | 2014-09-24 |
RU2014124118A (ru) | 2015-12-27 |
ZA201403735B (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2894892A1 (fr) | Derives d'acide boronique et leurs utilisations therapeutiques | |
WO2013170068A3 (fr) | Modulateurs du transport nucléaire et leurs utilisations | |
WO2012021715A3 (fr) | Formulations stables de linaclotide | |
EP2657231A4 (fr) | Azoles substitués, ingrédient actif antiviral, composition pharmaceutique et leur procédé de préparation et d'utilisation | |
ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
WO2010021607A3 (fr) | Préparation pharmaceutique | |
MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
IL231170A (en) | Nitrate mustard derivative compound, pharmaceutical preparation, use of drug preparation and compound for use as a drug | |
UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
WO2011141488A3 (fr) | Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone | |
WO2012162439A3 (fr) | Compositions comprenant de l'acide fusidique et leurs emballages | |
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
WO2012053013A3 (fr) | Compositions pharmaceutiques d'agents anti-acné | |
WO2012053009A3 (fr) | Compositions pharmaceutiques comprenant des agents de décoloration de la peau | |
EA201201109A1 (ru) | Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
WO2011002422A3 (fr) | Formulation pharmaceutique améliorant la solubilité | |
WO2011142731A3 (fr) | Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération | |
WO2012064304A3 (fr) | Combinaisions comprenant du montelukast | |
EP2871187A4 (fr) | Nouveau composé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique le contenant à titre de principe actif | |
WO2011139252A3 (fr) | Formulations effervescentes comprenant du cefdinir | |
BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
WO2011093831A3 (fr) | Formulations effervescentes contenant du cefprosil comme principe actif | |
WO2013072770A3 (fr) | Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride | |
IN2014DN10134A (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12826534 Country of ref document: EP Kind code of ref document: A2 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012826534 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012826534 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201406458 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2014124118 Country of ref document: RU Kind code of ref document: A |